SAM
NKTR icon

Smartleaf Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Smartleaf Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$130 Hold
2
– – ﹤0.01% 3380
2025
Q4 		$84 Buy
+2
New +$112 ﹤0.01% 3409
2024
Q4 		– Sell
-19
Closed -$329 – 2984
2024
Q3 		$329 Buy
+19
New +$362 ﹤0.01% 2835

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Smartleaf Asset Management's NKTR Position: Q1 2026 in Review

Smartleaf Asset Management held its Nektar Therapeutics (NKTR) position steady in Q1 2026 at 2 shares worth $130. The position accounts for ﹤0.01% of the portfolio, ranked #3380.

Smartleaf Asset Management first reported a position in NKTR in Q3 2024 and has held it in 3 quarters since. The position peaked at $329 in Q3 2024. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Smartleaf Asset Management held 2 shares of Nektar Therapeutics worth $130 as of Q1 2026.
  • Smartleaf Asset Management left its Nektar Therapeutics share count unchanged in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3380 holding.
  • Smartleaf Asset Management first reported a position in Nektar Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Smartleaf Asset Management's Nektar Therapeutics position peaked at $329 in Q3 2024.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.